カテゴリ： GlobalData, アメリカ, 企業調査

ZIOPHARM Oncology Inc (ZIOP)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：ZIOPHARM Oncology Inc (ZIOP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013131
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月27日
◆ページ数：78
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Ziopharm Oncology Inc (Ziopharm), formerly EasyWeb Inc is a biotechnology company that discovers and develops cancer therapies. The company develops novel gene expression, control and cell technologies to provides cell-based therapies for the treatment of cancer and graft-versus-host-disease (GvHD). It offers engineering techniques and multi-genic gene programs to develop next-generation patient and donor-derived adoptive cellular therapies. Ziopharm’s pipeline products include Ad-RTS-IL-12 and CAR/Cytokine Products. The company’s technology platforms comprise RheoSwitch therapeutic system, UltraVector, adoptive cell therapy, ActoBiotics, AttSite Recombinases and Leap among others. Its products and technologies are used in the treatment of hematologic malignancies, solid tumors and graft-versus-host-disease. Ziopharm is headquartered in Boston, Massachusetts, the US.

ZIOPHARM Oncology Inc (ZIOP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
ZIOPHARM, Intrexon Enter into Agreement with NCI 11
Intrexon Enters into Co-Development Agreement with Ziopharm Oncology 12
Ziopharm Expands Co-Development Agreement with Intrexon 13
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 14
Ziopharm Oncology Plans To Enter Into Co-Marketing Agreement For Palifosfamide 16
ZIOPHARM Oncology Enters Into Co-Development Agreement With Intrexon 17
Licensing Agreements 19
Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 19
Ziopharm Amends Licensing Agreement with Solasia Pharma for Darinaparsin 21
ZIOPHARM Oncology Enters Into Licensing Agreement With Solasia Pharma For Darinaparsin 23
Equity Offering 25
ZIOPHARM Oncology Prices Private Placement of Shares for USD50 Million 25
Ziopharm Oncology Completes Exercise of Over-Allotment Option of Public Offering of Shares for USD100.6 Million 26
Ziopharm Oncology Completes Public Offering Of Shares For US$50 Million 28
ZIOPHARM Oncology Completes Public Offering Of Common Stock For US$50 Million 29
ZIOPHARM Oncology Completes An Underwritten Public Offering Of US$63.5 Million 31
ZIOPHARM Oncology Inc – Key Competitors 33
ZIOPHARM Oncology Inc – Key Employees 34
ZIOPHARM Oncology Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Nov 06, 2017: ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities 36
Jul 31, 2017: ZIOPHARM Oncology Reports Second Quarter 2017 Financial Results and Provides Update on Recent Activities 39
May 01, 2017: Ziopharm Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities 42
Feb 16, 2017: ZIOPHARM Reports Fourth-Quarter 2016 Financial Results and Provides Update on Recent Activities 45
Nov 09, 2016: ZIOPHARM Reports Third Quarter 2016 Financial Results and Provides Update on Recent Activities 47
Aug 09, 2016: ZIOPHARM Reports Second-Quarter 2016 Financial Results and Provides Update on Recent Activities 50
May 10, 2016: ZIOPHARM Reports First-Quarter 2016 Financial Results and Provides Update on Recent Activities 52
Feb 24, 2016: ZIOPHARM Reports Fourth-Quarter 2015 Financial Results and Provides Update on Recent Activities 55
Corporate Communications 58
Sep 28, 2017: ZIOPHARM Oncology Appoints David Mauney, M.D., as Executive Vice President and Chief Business Officer 58
Legal and Regulatory 59
Jul 15, 2016: Federman & Sherwood Investigates ZIOPHARM Oncology for Possible Violations of Federal Securities Laws 59
Product News 60
11/15/2016: Sleeping Beauty System Used to Co-express CAR with Membrane-Bound IL-15 to Enhance Persistence of CD19-Specific T Cells 60
Oct 23, 2017: A Virus, a Gene and a Pill Used to Harness the Immune System to Fight Brain Tumor in Children 61
10/10/2016: ZIOPHARM Presents Data Demonstrating Activation of Anti-Tumor Immune Response Using Ad-RTS-hIL-12 in Patients with Advanced Breast Cancer 62
03/09/2016: Molecular Therapy Publication Highlights Sleeping Beauty Potential in Personalized TCR Gene Therapy 63
Feb 23, 2016: ZIOPHARM Announces Publication in Scientific Reports Describing Genetic Editing of Human Leukocyte Antigen in Cell Therapies to Broaden Their Human Application 64
Jan 11, 2016: ZIOPHARM Announces Sleeping Beauty Non-Viral Gene Transfer Technology Featured in Nature Medicine 65
Clinical Trials 66
Jan 31, 2017: ZIOPHARM Utilizing Non-Viral Sleeping Beauty Platform to Rapidly Produce CAR-Expressing T cells Advancing “Point-of-Care” Approach 66
Nov 17, 2016: ZIOPHARM Announces Clinical Data on Ad-RTS-hIL-12 Demonstrates Survival Benefits in Patients with Recurrent Brain Cancer 67
Jul 19, 2016: ZIOPHARM Provides Update Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer 68
Jul 15, 2016: ZIOPHARM Issues Statement Regarding Phase I Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer 69
Jul 12, 2016: ZIOPHARM Announces Plans for Phase I Clinical Trial with CD33 CAR-T Cell Therapy Targeting Acute Myeloid Leukemia 70
Jun 27, 2016: ZIOPHARM Completes Enrollment in Second Patient Cohort and Initiates Enrollment in Third Cohort in Phase 1 Study of Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer 71
May 18, 2016: ZIOPHARM Announces Clinical Data Highlighting Favorable Interim Survival Results with Gene Therapy Candidate Ad-RTS-hIL-12 in Brain Cancer 72
Apr 18, 2016: ZIOPHARM Announces Oral Presentation on AdRTSIL-12 at ASGCT 19th Annual Meeting 74
Apr 18, 2016: ZIOPHARM Announces Oral Presentation on Cancer Immunotherapy at ASGCT 19th Annual Meeting 75
Feb 24, 2016: ZIOPHARM Announces First Patient Treated in the Dose Escalation Portion of the Phase I Study of Ad-RTS-hIL-12 for Advanced Glioma 76
Feb 09, 2016: ZIOPHARM Announces First Patient Enrolled in Phase 1 Study of Second Generation Non-Viral CD19-Specific CAR T-Cell Therapy for Advanced Lymphoid Malignancies 77
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78

List of Tables
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
ZIOPHARM Oncology Inc, Deals By Therapy Area, 2011 to YTD 2017 9
ZIOPHARM Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
ZIOPHARM, Intrexon Enter into Agreement with NCI 11
Intrexon Enters into Co-Development Agreement with Ziopharm Oncology 12
Ziopharm Expands Co-Development Agreement with Intrexon 13
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 14
Ziopharm Oncology Plans To Enter Into Co-Marketing Agreement For Palifosfamide 16
ZIOPHARM Oncology Enters Into Co-Development Agreement With Intrexon 17
Intrexon, Ziopharm Oncology Enter into Licensing Agreement with University of Texas MD Anderson Cancer Center 19
Ziopharm Amends Licensing Agreement with Solasia Pharma for Darinaparsin 21
ZIOPHARM Oncology Enters Into Licensing Agreement With Solasia Pharma For Darinaparsin 23
ZIOPHARM Oncology Prices Private Placement of Shares for USD50 Million 25
Ziopharm Oncology Completes Exercise of Over-Allotment Option of Public Offering of Shares for USD100.6 Million 26
Ziopharm Oncology Completes Public Offering Of Shares For US$50 Million 28
ZIOPHARM Oncology Completes Public Offering Of Common Stock For US$50 Million 29
ZIOPHARM Oncology Completes An Underwritten Public Offering Of US$63.5 Million 31
ZIOPHARM Oncology Inc, Key Competitors 33
ZIOPHARM Oncology Inc, Key Employees 34
ZIOPHARM Oncology Inc, Subsidiaries 35

★海外企業調査レポート[ZIOPHARM Oncology Inc (ZIOP)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Hanwha Corp (000880)：企業の財務・戦略的SWOT分析
    Hanwha Corp (000880) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Exxon Mobil Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Exxon Mobil Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Exxon Mobil Corp (ExxonMobil) is an integrated oil and gas company that explores for and produces crude oil and natural gas; manufactures petroleum products; transports and sells crude oil and petro …
  • Synopsys Inc (SNPS)：企業の財務・戦略的SWOT分析
    Synopsys Inc (SNPS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Morinaga & Co., Ltd. (2201)：企業の財務・戦略的SWOT分析
    Morinaga & Co., Ltd. (2201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Bank Albilad：企業の戦略・SWOT・財務分析
    Bank Albilad - Strategy, SWOT and Corporate Finance Report Summary Bank Albilad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Plymouth Tube Company：企業の戦略的SWOT分析
    Plymouth Tube Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Euskaltel SA (EKT)：企業の財務・戦略的SWOT分析
    Euskaltel SA (EKT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • NantKwest Inc (NK)：企業の財務・戦略的SWOT分析
    Summary NantKwest Inc (NantKwest), a subsidiary of NantWorks LLC, formerly Conkwest Inc, is a clinical-stage immunotherapy company that develops therapeutic treatments for cancer, infectious diseases, and inflammatory diseases. The company utilizes its immuno-oncology NK platform to destroy the tumo …
  • Caldera Health Ltd：製品パイプライン分析
    Summary Caldera Health Ltd (Caldera) is a medical device company that develops prostate cancer diagnostic tools. The company develops prostate cancer diagnostic tools to detect and monitor the cancer disease. It also develops proscanZ and auditor tests based on the enzyme linked immunoassays or ELIS …
  • Marine Corps Community Services：企業の戦略・SWOT・財務情報
    Marine Corps Community Services - Strategy, SWOT and Corporate Finance Report Summary Marine Corps Community Services - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Paratek Pharmaceuticals Inc (PRTK)：企業の財務・戦略的SWOT分析
    Paratek Pharmaceuticals Inc (PRTK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Swire Pacific Ltd：企業の戦略・SWOT・財務情報
    Swire Pacific Ltd - Strategy, SWOT and Corporate Finance Report Summary Swire Pacific Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Hewlett Packard Enterprise Company：戦略・SWOT・企業財務分析
    Hewlett Packard Enterprise Company - Strategy, SWOT and Corporate Finance Report Summary Hewlett Packard Enterprise Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • GeoPetro Resources Company：石油・ガス：M&Aディール及び事業提携情報
    Summary GeoPetro Resources Company (GeoPetro), formerly GeoPetro Company is an oil and gas company that carries out exploration, production, and development of crude oil and natural gas resource prospects. The company’s projects include Madisonville (Rodessa) Field located to the north of Houston in …
  • Innocoll AG (INNL)-医療機器分野：企業M&A・提携分析
    Summary Innocoll AG (Innocoll), formerly Innocoll Holdings Inc is a specialty pharmaceutical company that carries out the development and manufacturing of surgical implants and topically applied healthcare products in the areas of unmet clinical needs. The company’s pipeline product portfolio includ …
  • Sprint Bioscience AB (SPRINT)：製薬・医療：M&Aディール及び事業提携情報
    Summary Sprint Bioscience AB (Sprint Bioscience) is a developer of pharmaceutical products in the areas of cancer and metabolism. The company develops STK25, a drug candidate against a new target protein for the treatment of type 2 diabetes; VPS34, a drug candidate for the treatment of various types …
  • Newhaven Hotels Limited：企業の戦略・SWOT・財務分析
    Newhaven Hotels Limited - Strategy, SWOT and Corporate Finance Report Summary Newhaven Hotels Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • DTEK Energy B.V.：電力：M&Aディール及び事業提携情報
    Summary DTEK Energy B.V. (DTEK Energy), formerly DTEK Holdings B.V., is a vertically-integrated utility that conducts coal mining and processing; electricity generation; manufacture of mining machinery; trading of coal and electricity in Ukrainian and international markets; and repair and maintenanc …
  • Compania Espanola de Petroleos SAU：企業の戦略的SWOT分析
    Compania Espanola de Petroleos SAU - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Lexmark International Inc (LXK)-医療機器分野：企業M&A・提携分析
    Summary Lexmark International Inc (Lexmark) is a provider of imaging and printing solutions. It manufactures, develops and supplies printing and imaging solutions, managed print services, device management, document workflow, business process and content management solutions. The company’s product p …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆